OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,720.00
-70.00 (-1.21%)
At close: Sep 4, 2026

OPTUS Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
13,75011,35810,30810,7605,0129,892
Depreciation & Amortization
5,0794,7083,9774,2383,4632,423
Loss (Gain) From Sale of Assets
34.3132.582.15-295.22-796.74-10.25
Loss (Gain) From Sale of Investments
-2,243-452.02-1,686-2,301566.27930.99
Stock-Based Compensation
-4.62-503.28519.1681.41--
Provision & Write-off of Bad Debts
--0.030.02-15.04-0.09-
Other Operating Activities
1,4501,7462,0692,771646.69-397.52
Change in Accounts Receivable
1,1082,465-4,171-1,852-1,151-2,438
Change in Inventory
1,841-2,564-77.42-1,800-2,112-3,043
Change in Accounts Payable
-775.99-885.21,235352.7517.23306.46
Change in Other Net Operating Assets
-510.37319.97-3,272497.8-3,601-592.48
Operating Cash Flow
19,72916,2258,90512,4382,0457,071
Operating Cash Flow Growth
115.90%82.21%-28.41%508.12%-71.08%-59.47%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-53,404-44,515-11,808-3,329-6,001-10,628
Sale of Property, Plant & Equipment
3610.82683.791,2922.9
Sale (Purchase) of Intangibles
-135.79-526.38-13,932---
Investment in Securities
-15,79413,22827,990-173.08-10,998-4,606
Other Investing Activities
0.5-4.07-16.3-78.03-536.2312.32
Investing Cash Flow
-69,333-31,7902,290-2,929-16,266-15,223

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
--1---
Total Debt Issued
--1---
Short-Term Debt Repaid
---1---
Long-Term Debt Repaid
--751.86-730.47-588.39-364.67-111.24
Total Debt Repaid
-802.96-751.86-731.47-588.39-364.67-111.24
Net Debt Issued (Repaid)
-802.96-751.86-730.47-588.39-364.67-111.24
Issuance of Common Stock
19,98310,090117.57---
Repurchase of Common Stock
-----5,958-
Dividends Paid
---1,526-1,517-1,604-1,604
Other Financing Activities
-7.67-7.67----
Financing Cash Flow
19,1729,331-2,139-2,105-7,927-1,715

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-37.810.1539.17-2.251.05-
Miscellaneous Cash Flow Adjustments
0-----0
Net Cash Flow
-30,470-6,2349,0957,402-22,146-9,867

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-33,676-28,290-2,9039,109-3,955-3,557
Free Cash Flow Growth
------
Free Cash Flow Margin
-35.65%-32.46%-3.55%12.58%-6.74%-6.21%
Free Cash Flow Per Share
-2047.33-1820.03-190.11599.36-249.37-221.87
Levered Free Cash Flow
-45,720-31,716-11,1695,838-4,902-4,264
Unlevered Free Cash Flow
-45,674-31,673-11,1085,915-4,848-4,258

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1.45-0120.1683.85-
Cash Income Tax Paid
1,856888.552,175930.792,0942,075
Change in Working Capital
1,662-664.66-6,285-2,801-6,846-5,767